LXLucy Xia

Lucy Xia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucy Xia has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Multiethnic Cohort: A Resource for the Study of Genetic and Nongenetic Cancer Risk across Populations

    by David Bogumil, Xin Sheng, Peggy Wan, Lucy Xia, Loreall Pooler, Iona Cheng, Samantha A. Streicher, Brian Z. Huang, Fei Chen, Daniel O. Stram, et al.

    Background: The Multiethnic Cohort Study (MEC) is a US prospective cohort of more than 215,000 participants, designed to investigate variation in risk factors and disease across diverse racial and ethnic groups. More than 74,000 participants contributed biospecimens for genetic studies. We describe this subcohort and demonstrate the types of analyses it enables. Methods: The MEC recruited adults aged 45 to 75 in California and Hawaii between 1993 and 1996. Cancer diagnoses were identified via state tumor registries. The MEC Genetics Database includes 73,139 participants with germline genotype data. We evaluated genetic similarity, its relationship with self-reported race/ethnicity, and baseline characteristics, including neighborhood socioeconomic status (nSES). Using breast, colorectal, and prostate cancer as examples, we conducted genome-wide association studies (GWAS), assessed nongenetic risk factors, and performed time-to-event analyses. Results: Participants included 10,962 African Americans, 24,234 Japanese Americans, 17,242 Latinos, 5,488 Native Hawaiians, 14,649 Whites, and 564 others. Principal component analysis showed substantial diversity. Multiethnic GWAS replicated known variants with effective control of population stratification. Polygenic risk score (PRS) effects varied across groups. Time-to-event models revealed associations between cancer incidence and nSES, population descriptors, and genetic similarity. Conclusions: The MEC Genetics Database enables multiancestry analyses of genetic and nongenetic cancer risk, supporting research on disparities, polygenic traits, and integrated risk prediction. Impact: Example analyses using these resources show the relationship between population descriptors, PRSs, and common cancer risk factors that require special consideration in genetic analyses.


  • Open Access

    Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry

    by Raymond W. Hughley, Marco Matejcic, Ziwei Song, Xin Sheng, Peggy Wan, Lucy Xia, Steven N. Hart, Chunling Hu, Siddhartha Yadav, Alexander Lubmawa, et al.

    Prostate cancer risk is influenced by rare and common germline variants. We examined the aggregate association of rare germline pathogenic/likely pathogenic/deleterious (P/LP/D) variants in ATM, BRCA2, PALB2, and NBN with a polygenic risk score (PRS) on prostate cancer risk among 1,796 prostate cancer cases (222 metastatic) and 1,424 controls of African ancestry. Relative to P/LP/D non-carriers at average genetic risk (33%–66% of PRS), men with low (0%–33%) and high (66%–100%) PRS had Odds Ratios (ORs) for overall prostate cancer of 2.08 [95% confidence interval (CI) = 0.58–7.49] and 18.06 (95% CI = 4.24–76.84) among P/LP/D carriers and 0.57 (95% CI = 0.46–0.71) and 3.02 (95% CI = 2.53–3.60) among non-carriers, respectively. The OR for metastatic prostate cancer was 2.73 (95% CI = 0.24–30.54) and 28.99 (95% CI = 4.39–191.43) among P/LP/D carriers and 0.54 (95% CI = 0.31–0.95) and 3.22 (95% CI = 2.20–4.73) among non-carriers, for men with low and high PRS, respectively. Lifetime absolute risks of overall prostate cancer increased with PRS (low to high) from 9.8% to 51.5% in P/LP/D carriers and 5.5% to 23.9% in non-carriers. Lifetime absolute risks of metastatic prostate cancer increased with PRS from 1.9% to 18.1% in P/LP/D carriers and 0.3% to 2.2% in non-carriers These findings suggest that assessment of prostate cancer risk for rare variant carriers should include PRS status. Significance: These findings highlight the importance of considering rare and common variants to comprehensively assess prostate cancer risk in men of African ancestry.